%A Xu, Kuan 
%A Zhu, Yan 
%A Hu, Gang 
%D 2024
%T Efficacy of Compound Danshen Dripping Pills in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis
%! Efficacy of Compound Danshen Dripping Pills in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis
%K Compound Danshen Dripping Pills, acute myocardial infarction, percutaneous coronary intervention, meta-analysis
%X Aims: The objective of this meta-analysis was to determine the efficacy of Compound Danshen Dripping Pills (CDDP) in patients experiencing acute myocardial infarction (AMI) who are undergoing percutaneous coronary intervention (PCI).
Methods: We conducted a comprehensive systematic search on multiple databases, including PubMed, Embase, Cochrane Library, and Web of Science, for pertinent studies published up until March 2024. The selection criteria included studies that clearly mentioned the use of CDDP in patients with AMI undergoing PCI. Primary outcomes that were measured included Left Ventricular Ejection Fraction (LVEF), Left Ventricular End Systolic Diameter (LVESD), Left Ventricular End Diastolic Diameter (LVEDD), cardiac troponin I and T (cTnI/cTnT), Brain Natriuretic Peptide (BNP), and Tumor Necrosis Factor-alpha (TNF-a). We employed rigorous statistical methods for data extraction and synthesis. Heterogeneity across studies was assessed using I2 statistics. Sensitivity analyses were performed to ensure the robustness of the findings, and funnel plots were used to visually inspect for potential publication bias.
Results: Our meta-analysis incorporated a total of 9 articles with a sample size of 1,099. Our analysis of pooled data from a series of case-control studies showed a significant increase in LVEF in patients who received CDDP along with standard care, compared to those who received only standard care (Standard Mean Difference (SMD) 0.77, 95% Confidence Interval (CI) 0.49–1.06). Furthermore, CDDP treatment was associated with a significant decrease in LVESD (SMD −0.67, 95% CI −1.05 to −0.29), LVEDD (SMD −0.96, 95% CI −1.45 to −0.48), cTnI/cTnT (SMD −2.70, 95% CI −4.31 to −1.09), BNP (SMD −2.66, 95% CI −4.06 to −1.25), and TNF-a (SMD −1.75, 95% CI −2.66 to −0.84). These findings suggest that CDDP, when used in combination with standard care, may improve cardiac function and decrease myocardial injury and inflammation in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Conclusion: Our meta-analysis suggests that the combination of CDDP and standard care significantly improves cardiac function and reduces myocardial injury and inflammation in patients with AMI undergoing PCI. These findings indicate a potential protective role of CDDP. However, further large-scale randomized controlled trials are required to confirm these results and assess the long-term effects and safety of CDDP in this patient group.
%U https://doi.org/10.18632/aging.206000
%J Aging
%0 Journal Article
%R 10.18632/aging.206000
%@ 1945-4589